Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

GLP-1 agonist medications ... Adults with diabetes lost 12.8% to 14.7% of their body weight. In comparison, placebo groups saw weight reductions of only 3.1% (without diabetes) and 3.2% (with ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Nearly half of patients with type 2 diabetes and two-thirds without discontinue GLP-1 receptor agonists within a year, with weight loss, income, and adverse events influencing discontinuation and ...

Use of GLP-1 receptor agonists reduced the risk of kidney failure and individual MACE components compared with placebo among patients with or without diabetes. Glucagon-like peptide-1 receptor ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...